The global viscosupplementation market is projected to reach US$ 2,167.3 million in 2024. The viscosupplementation demand is expected to witness a robust CAGR of 5.7% from 2024 to 2034. By 2034, the sales of viscosupplementation are anticipated to attain a valuation of US$ 3,777.4 million.
The rising prevalence of osteoarthritis (OA) fosters the demand for viscosupplementation. The viscosupplementation treatment market is expected to be driven by the increasing number of people seeking non-surgical treatment for osteoarthritis and lifestyle-related illnesses and developments in the creation of hyaluronic acid-based therapies.
Get your Sample Report with Latest Market Information: https://www.futuremarketinsights.com/reports/sample/rep-gb-9509
The market is expected to develop since the existing viscosupplements are clinically beneficial and the most effective alternative for treating osteoarthritis in the knee. Another aspect influencing the viscosupplementation market growth is the aging population.
Compared to other therapy forms, viscosupplementation treatments are anticipated to be relatively expensive. Economics has a detrimental role in the widespread adoption of viscosupplementation, particularly in areas where healthcare budgets are tight.
Strict regulatory standards and approval procedures will likely hinder growth in the viscosupplementation treatment market. Delays in viscosupplementation product launches and higher development costs are the consequences of regulatory hurdles.
Regional Outlook:
The Asia Pacific region controls the viscosupplementation market with a significant revenue share. The older population in this area is one of the primary factors propelling the viscosupplementation industry. They are more susceptible to osteoarthritis. Due to cultural norms, apprehension about surgery, and a wish to prevent complications following surgery, a large number of people in the Asia Pacific region favor non-surgical treatment methods.
Due to factors including the growing senior population, the rising prevalence of osteoarthritis and related ailments, the well-developed healthcare infrastructure, and the ever-increasing desire for non-surgical procedures, the North America viscosupplementation treatment market is expected to grow. The main catalyst of the viscosupplementation demand is the growing prevalence of osteoarthritis, arthritis, and knee pain.
“The increasing incidence of osteoarthritis is fueling the potential growth of the global viscosupplementation treatment market. A larger number of people are getting older, which increases the need for less invasive therapies. Advances in healthcare and patient preference for non-surgical treatments are expected to propel viscosupplementation market expansion.” Opines Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Reach Out to Our Analyst For Further Clarity: https://www.futuremarketinsights.com/ask-question/rep-gb-9509
Key Takeaways:
- The three-injection viscosupplementation segment in the product category to grab a share of 48.4% from 2024 to 2034.
- In the end user category, the ambulatory surgical center’s segment is to acquire a market share of 31.9% between 2024 and 2034.
- The United States sales of viscosupplementation are anticipated to surge at a CAGR of 3.9% from 2024 to 2034.
- Germany’s viscosupplementation market is to develop at a CAGR of 4.0% through 2024.
- China’s sales of viscosupplementation are expected to surge at a CAGR of 9.0% from 2024 to 2034.
- Brazil’s viscosupplementation industry is anticipated to boost at a CAGR of 6.2% between 2024 and 2034.
- Japan’s viscosupplementation market is likely to exhibit a CAGR of 8.5% from 2024 to 2034.
Competitive Landscape:
Prominent viscosupplementation producers are concentrating on creating cross-linked hyaluronic acid to relieve immediate pain. The viscosupplementation manufacturers are investing heavily to get a competitive edge over one another. New products are introduced, and the industry is expanding into new regions in the viscosupplementation treatment market.
Noteworthy Developments:
- An agreement to license TissueGene-C low dose (TG-C LD), a non-surgical experimental treatment given as a single intra-articular injection to treat knee osteoarthritis, was made in April 2022 between Juniper Biologics and Kolon Life Sciences.
- The joint function enhancement agent JOYCLU 30 mg intra-articular injection was introduced in May 2021 by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation. Seikagaku was granted manufacturing and marketing approval for the product in Japan in March 2021.
- The International Cartilage Regeneration and Joint Preservation Society (ICRS) hosted the official launch of Hyalofast, a hyaluronic acid-based scaffold for cartilage regeneration, by Anika Therapeutics, Inc.
Personalization Redefined: Embrace Customization in Our Resourceful Report: https://www.futuremarketinsights.com/customization-available/rep-gb-9509
Prominent Viscosupplementation Manufacturers:
- Sanofi S.A.
- Zimmer Biomet Holdings Inc.
- Bioventus LLC
- Anika Therapeutics Inc.
- Fidia Farmaceutici S.p.A.
- Ferring B.V.
- Seikagaku Corporation
- Chugai Pharmaceutical Co., Ltd.
- OrthogenRx Inc.
- Mylan N.V.
Key Segments:
By Product:
- Single Injection Viscosupplementation
- Three Injection Viscosupplementation
- Five Injection Viscosupplementation
By Application:
- Knee Osteoarthritis
- Hip Osteoarthritis
- Shoulder Osteoarthritis
- Others
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Orthopedic Clinics
- Retail Pharmacies
- Online Sales
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia and Pacific
- Middle East and Africa
Act Now to Explore In-Depth Market Analysis: Get Exclusive Discount Now to Access Market Trends: https://www.futuremarketinsights.com/checkout/9509
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube